Cart
0
Get 20% Free Customization In This Report
Buy this report from - $3321

Preimplantation Genetics Diagnosis (PGD) Market By Test Type (Chromosomal Abnormalities, Aneuploidy, X-linked diseases, Single Gene Disorders, HLA Typing, Gender selection) - Global Opportunity Analysis and Industry Forecast, 2014-2022

LI 161470
Pages: 100
Dec 2016 | 1650 Views
face gplus_n
Author's : Sriram Radhakrishnan
Tables: 58
Charts: 18
twit_n pr_n

PGD Market Overview:

Preimplantation Genetic Diagnosis (PGD) market size was valued at $79 million, and is expected to reach $121 million by 2022, supported by a CAGR of 6.14%. Preimplantation genetic diagnosis (PGD) also referred as embryo screening, is a branch of genetics involves in genetic testing of embryo through In-Vitro fertilization (IVF). PGD eliminates risk of selective pregnancy termination for couples who are at substantial risk of transferring serious genetic, chromosomal or hereditary disorders such as spinal muscular atrophy and cystic fibrosis.


The world PGD market is expected to witness notable growth in the coming years owning to the rising prevalence of genetic, hereditary and chromosomal diseases. Moreover, PGD have high chances of conceiving healthy embryos. However, the high costs incurred in the PGD technologies hamper the growth of the market. Moreover, stringent government regulations and ethical concerns also obstruct the growth of the market. In coming years, there would be increase in adoption of PGD worldwide owning to the various applications of PGD for development of healthy embryo.

Segment Review

The world PGD market encompasses various test types and geography. The test type segment namely chromosomal abnormalities, gender selection, X-linked diseases, aneuploidy, single gene disorders and others are covered under the scope of the report. Based on geography, the world PGD market is segmented into North America, Europe, Asia-Pacific, and LAMEA.
 
Segment Overview

Segment Overview

At present, chromosomal abnormalities segment has witnessed large-scale adoption of PGD market. Single gene disorders, aneuploidy and X-linked disease are some of the other segments in world PGD market. These segments are anticipated to witness increase in market share due to growing genetic, hereditary and chromosomal diseases. However, stringent government regulations related to use of PGD have hindered the market growth of PGD market. Furthermore, gender selection is anticipated grow owning to increasing gender imbalance. However, stringent government regulations and restriction of gender selection have hindered the market growth of this segment.
 
TOP INVESTMENT POCKETS

TOP INVESTMENT POCKETS

The significant impacting factors include effective embryo development and diverse PGD applications such as, overcoming infertility, chromosomal and hereditary disorders. All these factors collectively create opportunities for the market growth whilst some of the factors pose limitations in the market. However, each factor would have its definite impact on the market during the forecast period.
 
TOP IMPACTING FACTORS

TOP IMPACTING FACTORS

The key players operating in the world PGD market are Reprogenetics, LLC, Genea Limited, Illumina, Inc., Laboratory Corporation of America Holdings, Natera, Inc., PerkinElmer, Inc., Quest Diagnostics Incorporated, Genesis Genetics Ltd., and Reproductive Genetics Innovations LLC.

KEY MARKET BENEFITS:

  • In-depth study of the global preimplantation genetic diagnostic market was conducted based on current testing trends of genetic test and based on the preferences for designer babies
  • Potential analysis of opportunities was evaluated for understanding different aspects of preimplantation genetic test that are currently under various phases of clinical trials along with the variants that would gain prominence in the future
  • A deep analysis of key market dynamics that influence the adoption of PGD tests in the forecast period
  • Analysis of volume and vale share analysis of PGD testing at a global and regional level
  • Key market players are profiled and their strategies are analyzed thoroughly for understanding the various technologies adopted by them for development and production of diagnostic tests for PGD testing

KEY MARKET SEGMENT:

By Test Type

  • Chromosomal abnormalities
  • Gender selection
  • X-linked diseases
  • Aneuploidy
  • Single gene disorders
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • LAMEA
 

Chapter: 1 INTRODUCTION

1.1 Report Description
1.2 Key Benefits
1.3 Key Market Segments:
1.4 Research methodology

1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

2.1 CXO perspective

Chapter: 3 MARKET OVERVIEW

3.1 Market definition and scope
3.2 Key findings

3.2.1 Top impacting factor
3.2.2 Top winning strategies
3.2.3 Top investment pockets

3.3 Porters five forces analysis

3.3.1 Low bargaining power of suppliers due to large number of suppliers and moderate switching cost
3.3.2 Moderate bargaining power of buyers due to large number of buyers, high product dependency and moderate switching cost.
3.3.3 Moderate threat of substitutes due to ease of substitution, moderate price war and high brand loyalty
3.3.4 Low threat of new entrants due to presence of dominant players and high investment cost and legal barriers
3.3.5 Presence of numerous players, high growth rate and high economic base increases the competition among rivalries

3.4 Drivers

3.4.1 Effective solution for the healthy embryos
3.4.2 Increasing infertility rate and genetic, hereditary and chromosomal diseases
3.4.3 Innovative and wide range of applications such as development of savior siblings and gender selection among others

3.5 Restraints

3.5.1 Stringent regulations and ethical concerns
3.5.2 High cost incurred and risk involved in PGD

3.6 Opportunities

3.6.1 Increasing adoption of PGD in developing countries

Chapter: 4 WORLD PGD MARKET, BY TEST TYPE

4.1 Introduction
4.2 Chromosomal Abnormalities

4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.2.4 North America Chromosomal Abnormalities Market, Growth (%) 2014-2022
4.2.5 Europe Chromosomal Abnormalities Market, Growth (%) 2014-2022
4.2.6 Asia Pacific Chromosomal Abnormalities Market, Growth (%) 2014-2022
4.2.7 LAMEA Chromosomal Abnormalities Market, Growth (%) 2014-2022

4.3 Aneuploidy

4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast
4.3.4 North America Aneuploidy Market, Growth (%) 2014-2022
4.3.5 Europe Aneuploidy Market, Growth (%) 2014-2022
4.3.6 Asia Pacific Aneuploidy Market, Growth (%) 2014-2022
4.3.7 LAMEA Aneuploidy Market, Growth (%) 2014-2022

4.4 X-linked Diseases

4.4.1 Key market trends
4.4.2 Key growth factors and opportunities
4.4.3 Market size and forecast
4.4.4 North America X-Linked Diseases Market, Growth (%) 2014-2022
4.4.5 Europe X-Linked Diseases Market, Growth (%) 2014-2022
4.4.6 Asia Pacific X-Linked Diseases Market, Growth (%) 2014-2022
4.4.7 LAMEA X-Linked Diseases Market, Growth (%) 2014-2022

4.5 Single Gene Disorders

4.5.1 Key market trends
4.5.2 Key growth factors and opportunities
4.5.3 Market size and forecast
4.5.4 North America Single Gene Disorders Market, Growth (%) 2014-2022
4.5.5 Europe Single Gene Disorders Market, Growth (%) 2014-2022
4.5.6 Asia Pacific Single Gene Disorders Market, Growth (%) 2014-2022
4.5.7 LAMEA Single Gene Disorders Market, Growth (%) 2014-2022

4.6 HLA Typing

4.6.1 Key market trends
4.6.2 Key growth factors and opportunities
4.6.3 Market size and forecast
4.6.4 North America HLA Typing Market, Growth (%) 2014-2022
4.6.5 Europe HLA Typing Market, Growth (%) 2014-2022
4.6.6 Asia Pacific HLA Typing Market, Growth (%) 2014-2022
4.6.7 LAMEA HLA Typing Market, Growth (%) 2014-2022

4.7 Gender selection

4.7.1 Key market trends
4.7.2 Key growth factors and opportunities
4.7.3 Market size and forecast
4.7.4 North America Gender Selection Market, Growth (%) 2014-2022
4.7.5 Europe Gender Selection Market, Growth (%) 2014-2022
4.7.6 Asia Pacific Gender Selection Market, Growth (%) 2014-2022
4.7.7 LAMEA Gender Selection Market, Growth (%) 2014-2022

4.8 Others PGD Test (Disability and Adult Onset Disease)

4.8.1 Key market trends
4.8.2 Key growth factors and opportunities
4.8.3 Market size and forecast
4.8.4 North America Others PGD Market, Growth (%) 2014-2022
4.8.5 Europe Others PGD Market, Growth (%) 2014-2022
4.8.6 Asia Pacific Others PGD Market, Growth (%) 2014-2022
4.8.7 LAMEA Others PGD Market, Growth (%) 2014-2022

Chapter: 5 WORLD PGD MARKET, BY GEOGRAPHY

5.1 Introduction
5.2 North America

5.2.1 Key market trends
5.2.2 Key growth factors and opportunities
5.2.3 Market size and forecast

5.3 Europe

5.3.1 Key market trends
5.3.2 Key growth factors and opportunities
5.3.3 Market size and forecast

5.4 Asia Pacific (APAC)

5.4.1 Key market trends
5.4.2 Key growth factors and opportunities
5.4.3 Market size and forecast

5.5 LAMEA

5.5.1 Key market trends
5.5.2 Key growth factors and opportunities
5.5.3 Market size and forecast

Chapter: 6 COMPANY PROFILE

6.1 Reprogenetics, LLC.

6.1.1 Company Snapshot
6.1.2 Operating business segments
6.1.3 Business performance
6.1.4 Key strategies & developments

6.2 F. Hoffmann-La Roche AG

6.2.1 Company Snapshot
6.2.2 Operating business segments
6.2.3 Business performance
6.2.4 Key strategies & developments

6.3 Genea Limited

6.3.1 Company overview
6.3.2 Company Snapshot
6.3.3 Operating business segments
6.3.4 Business performance
6.3.5 Key strategies & developments

6.4 Illumina, Inc

6.4.1 Company overview
6.4.2 Company Snapshot
6.4.3 Operating business segments
6.4.4 Business performance
6.4.5 Key strategies & developments

6.5 Laboratory Corporation of America Holdings

6.5.1 Company overview
6.5.2 Company Snapshot
6.5.3 Operating business segments
6.5.4 Business performance
6.5.5 Key strategies & developments

6.6 Natera, Inc

6.6.1 Company overview
6.6.2 Company Snapshot
6.6.3 Operating business segments
6.6.4 Business performance
6.6.5 Key strategies & developments

6.7 PerkinElmer, Inc

6.7.1 Company overview
6.7.2 Company Snapshot
6.7.3 Operating business segments
6.7.4 Business performance
6.7.5 Key strategies & developments

6.8 Genesis Genetics Ltd

6.8.1 Company overview
6.8.2 Company Snapshot
6.8.3 Operating business segments
6.8.4 Business performance
6.8.5 Key strategies & developments

6.9 Reproductive Genetics Innovations LLC.

6.9.1 Company overview
6.9.2 Company Snapshot
6.9.3 Operating business segments
6.9.4 Business performance
6.9.5 Key strategies & developments

6.10 Quest Diagnostics Inc.

6.10.1 Company overview
6.10.2 Company Snapshot
6.10.3 Operating business segments
6.10.4 Business performance
6.10.5 Key strategies & developments

List of Finger

FIG. 1 TOP IMPACTING FACTORS
FIG. 2 TOP WINNING STRATEGIES IN THE PGD MARKET (20132016)
FIG. 3 TOP WINNING STRATEGIES (%) (20132016)
FIG. 4 TOP INVESTMENT POCKETS
FIG. 5 PORTERS FIVE FORCES ANALYSIS OF PRE-IMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET
FIG. 6 WORLD PGD MARKET BY PRODUCT TYPE, 2015 (PIE CHART OF GLOBAL NUMBERS BY PRODUCT TYPE) REVENUE
FIG. 7 WORLD CHROMOSOMAL ABNORMALITIES MARKET Y-O-Y(%), 2015-2022
FIG. 8 WORLD ANEUPLOIDY MARKET, Y-OY (%), 2015-2022
FIG. 9 WORLD X-LINKED DISEASES MARKET, BY Y-OY (%), 2015-2022
FIG. 10 WORLD PGD SINGLE GENE DISORDERS MARKET, Y-O-Y (%), 2015-2022
FIG. 11 WORLD HLA TYPING MARKET, YOY (%), 2015-2022
FIG. 12 WORLD PGD GENDER SELECTION MARKET, Y-O-Y (%), 2015-2022
FIG. 13 WORLD PGD OTHERS MARKET, Y-OY (%), 2015-2022
FIG. 14 WORLD PGD MARKET BY GEOGRAPHY, 2015 (PIE CHART OF GLOBAL NUMBERS BY GEOGRAPHY) REVENUE
FIG. 15 NORTH AMERICA PGD MARKET, YEAR ON YEAR GROWTH(%), 2015-2022
FIG. 16 EUROPE PGD MARKET, YEAR ON YEAR GROWTH(%), 2015-2022
FIG. 17 APAC PGD MARKET, YEAR ON YEAR GROWTH(%), 2015-2022
FIG. 18 LAMEA PGD MARKET, YEAR ON YEAR GROWTH(%), 2015-2022

List of Tables

TABLE 1 PGD SUCCESS RATES BY THE HUMAN FERTILISATION AND EMBRYOLOGY AUTHORITY (HEFA)
TABLE 2 WORLD CHROMOSOMAL ABNORMALITIES MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 3 NORTH AMERICA CHROMOSOMAL ABNORMALITIES MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 4 EUROPE CHROMOSOMAL ABNORMALITIES MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 5 ASIA PACIFIC CHROMOSOMAL ABNORMALITIES MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 6 LAMEA CHROMOSOMAL ABNORMALITIES MARKET, BY REVENUE BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 7 WORLD ANEUPLOIDY MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 8 NORTH AMERICA ANEUPLOIDY MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 9 EUROPE ANEUPLOIDY MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 10 ASIA PACIFIC ANEUPLOIDY MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 11 LAMEA ANEUPLOIDY MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 12 WORLD X-LINKED DISEASES MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 13 NORTH AMERICA X-LINKED DISEASES MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 14 EUROPE X-LINKED DISEASES MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 15 ASIA PACIFIC X-LINKED DISEASES MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 16 LAMEA X-LINKED DISEASES MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 17 WORLD SINGLE GENE DISORDERS MARKET, BY REVENUE ($MILLION), GROWTH (%)2014-2022
TABLE 18 NORTH AMERICA SINGLE GENE DISORDERS MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 19 EUROPE SINGLE GENE DISORDERS MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 20 ASIA PACIFIC SINGLE GENE DISORDERS MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 21 LAMEA SINGLE GENE DISORDERS MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 22 WORLD HLA TYPING MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 23 NORTH AMERICA HLA TYPING MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 24 EUROPE HLA TYPING MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 25 ASIA PACIFIC HLA TYPING MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 26 LAMEA HLA TYPING MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 27 WORLD GENDER SELECTION MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 28 NORTH AMERICA GENDER SELECTION MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 29 EUROPE GENDER SELECTION MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 30 ASIA PACIFIC GENDER SELECTION MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 31 LAMEA GENDER SELECTION MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 32 WORLD OTHERS PGD TESTING MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 33 NORTH AMERICA OTHERS PGD MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 34 EUROPE OTHERS PGD MARKET, ($MILLION), GROWTH (%) 2014-2022
TABLE 35 ASIA PACIFIC OTHERS PGD MARKET, ($MILLION), GROWTH (%) 2014-2022
TABLE 36 LAMEA OTHERS PGD MARKET, ($MILLION), GROWTH (%) 2014-2022
TABLE 37 NORTH AMERICA PGD MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 38 EUROPE PGD MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 39 ASIA PACIFIC PGD MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 40 LAMEA PGD MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 41 REPROGENETICS, LLC.: COMPANY SNAPSHOT
TABLE 42 REPROGENETICS, LLC.: OPERATING SEGMENTS
TABLE 43 REPROGENETICS, LLC.: COMPANY SNAPSHOT
TABLE 44 REPROGENETICS, LLC.: OPERATING SEGMENTS
TABLE 45 GENEA LIMITED.: COMPANY SNAPSHOT
TABLE 46 GENEA LIMITED.: OPERATING SEGMENTS
TABLE 47 ILLUMINA, INC.: COMPANY SNAPSHOT
TABLE 48 ILLUMINA, INC.: OPERATING SEGMENTS
TABLE 49 LABORATORY CORPORATION OF AMERICA HOLDINGS.: COMPANY SNAPSHOT
TABLE 50 LABORATORY CORPORATION OF AMERICA HOLDINGS.: OPERATING SEGMENTS
TABLE 51 NATERA, INC.: COMPANY SNAPSHOT
TABLE 52 NATERA, INC: OPERATING SEGMENTS
TABLE 53 GENESIS GENETICS LTD.: COMPANY SNAPSHOT
TABLE 54 GENESIS GENETICS LTD: OPERATING SEGMENTS
TABLE 55 REPRODUCTIVE GENETICS INNOVATIONS LLC: COMPANY SNAPSHOT
TABLE 56 REPRODUCTIVE GENETICS INNOVATIONS LLC: OPERATING SEGMENTS
TABLE 57 QUEST DIAGNOSTICS INC: COMPANY SNAPSHOT
TABLE 58 QUEST DIAGNOSTICS INC.: OPERATING SEGMENTS

 

PGD provides effective solution for the healthy embryos free from genetic, hereditary, and chromosomal disorders. In addition, increase in prevalence of hereditary, chromosomal, and genetic disorders like triploidy, thalassemia, and duchenne muscular dystrophy (DMD) rise every year, which requires PGD for the diagnosis of mutational changes. Moreover, increase in usage of PGD techniques in selecting human leukocyte antigen (HLA) profile to match existing sibling with the disease and sex balancing in family have also spurred the market growth. In addition, PGD has shown positive response in patients trying to conceive with recurrent IVF failures, low sperm count, and with advance maternal age.

Through PGD, it is possible to develop “perfect tailor made babies” by selecting features like gender, intelligence, beauty, and height during screening embryos, which have given scope for critics from religious conservatives to advocates for rising new age of eugenics. In addition, it also raises concerns regarding discrimination toward disabled and intersex people. Moreover, misuse of PGD in gender selections and condemnation from some religious organizational for this procedure hamper the market growth. Many countries like Switzerland, Austria, and India have reported limited usage of PGD for medical purposes.

The market is largely driven by the merger and acquisition. Business expansion and partnership are other prominent strategies adopted by key market players to remain competitive. Almost 33% of the top strategies were merger and acquisition; whereas, business expansion, partnership, and product launch accounted for 25, 22.22, and 19.44%, respectively, of the overall key strategies.

The key market players are Reprogenetics, LLC, Genea Limited, Illumina, Inc., Laboratory Corporation of America Holdings, Natera, Inc., PerkinElmer, Inc., Quest Diagnostics Incorporated, Genesis Genetics Ltd., and Reproductive Genetics Innovations LLC.

 

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

 

Get More Information About This Report

For any queries about purchasing this report, Please fill the form below:

Please input the above text in the input box or click refresh

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts